InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025
InMed Pharmaceuticals (NASDAQ: INM) announced the presentation of new preclinical data for its INM-901 drug candidate at the upcoming Alzheimer's Association International Conference (AAIC) 2025 in Toronto. The study evaluated INM-901's long-term treatment effects in a 5xFAD mouse model of advanced Alzheimer's disease.
The research demonstrated that INM-901 showed multiple positive effects, including: reduction in inflammatory biomarkers, decreased amyloid-beta immunoreactivity, partial restoration of MAP2 protein, and improvements in cognitive function. The drug candidate exhibited dose-dependent therapeutic effects in neuroinflammation and showed promise in restoring behavioral and sensory responses to normal levels.
The data will be presented in a scientific poster titled "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study" at AAIC 2025, scheduled for July 27-31.
InMed Pharmaceuticals (NASDAQ: INM) ha annunciato la presentazione di nuovi dati preclinici per il suo candidato farmaco INM-901 alla prossima Conferenza Internazionale dell'Alzheimer's Association (AAIC) 2025 a Toronto. Lo studio ha valutato gli effetti del trattamento a lungo termine di INM-901 in un modello murino 5xFAD di Alzheimer in fase avanzata.
La ricerca ha dimostrato che INM-901 ha mostrato molteplici effetti positivi, tra cui: riduzione dei biomarcatori infiammatori, diminuzione dell'immunoreattività dell'amiloide-beta, parziale ripristino della proteina MAP2 e miglioramenti nella funzione cognitiva. Il candidato farmaco ha evidenziato effetti terapeutici dose-dipendenti sulla neuroinfiammazione e ha mostrato potenzialità nel ripristinare risposte comportamentali e sensoriali a livelli normali.
I dati saranno presentati in un poster scientifico intitolato "Potenziale terapeutico di INM-901 nella mitigazione della patologia dell'Alzheimer: approfondimenti da uno studio a lungo termine su modello murino 5xFAD" durante l'AAIC 2025, in programma dal 27 al 31 luglio.
InMed Pharmaceuticals (NASDAQ: INM) anunció la presentación de nuevos datos preclínicos para su candidato a fármaco INM-901 en la próxima Conferencia Internacional de la Asociación de Alzheimer (AAIC) 2025 en Toronto. El estudio evaluó los efectos del tratamiento a largo plazo de INM-901 en un modelo murino 5xFAD de Alzheimer avanzado.
La investigación demostró que INM-901 mostró múltiples efectos positivos, incluyendo: reducción de biomarcadores inflamatorios, disminución de la inmunorreactividad de la beta-amiloide, restauración parcial de la proteína MAP2 y mejoras en la función cognitiva. El candidato a fármaco exhibió efectos terapéuticos dependientes de la dosis en neuroinflamación y mostró potencial para restaurar las respuestas conductuales y sensoriales a niveles normales.
Los datos serán presentados en un póster científico titulado "Potencial terapéutico de INM-901 para mitigar la patología de la enfermedad de Alzheimer: perspectivas de un estudio a largo plazo en el modelo murino 5xFAD" en la AAIC 2025, programada del 27 al 31 de julio.
InMed Pharmaceuticals (NASDAQ: INM)는 토론토에서 열리는 2025년 알츠하이머 협회 국제 학술대회(AAIC)에서 신약 후보물질 INM-901의 새로운 전임상 데이터를 발표한다고 밝혔습니다. 본 연구는 진행된 알츠하이머병의 5xFAD 마우스 모델에서 INM-901의 장기 치료 효과를 평가했습니다.
연구 결과 INM-901은 여러 긍정적인 효과를 보였으며, 염증성 바이오마커 감소, 아밀로이드 베타 면역반응 감소, MAP2 단백질 부분 회복, 인지 기능 개선 등이 포함됩니다. 해당 후보물질은 신경염증에 대해 용량 의존적 치료 효과를 나타냈으며 행동 및 감각 반응을 정상 수준으로 회복시키는 가능성을 보여주었습니다.
이 데이터는 7월 27일부터 31일까지 예정된 AAIC 2025에서 "장기 5xFAD 마우스 모델 연구를 통한 INM-901의 알츠하이머병 병리 완화 치료 가능성"이라는 제목의 과학 포스터로 발표될 예정입니다.
InMed Pharmaceuticals (NASDAQ : INM) a annoncé la présentation de nouvelles données précliniques concernant son candidat-médicament INM-901 lors de la prochaine Conférence Internationale de l'Association Alzheimer (AAIC) 2025 à Toronto. L'étude a évalué les effets d'un traitement à long terme avec INM-901 dans un modèle murin 5xFAD de la maladie d'Alzheimer avancée.
La recherche a montré que INM-901 a présenté plusieurs effets positifs, notamment : réduction des biomarqueurs inflammatoires, diminution de l'immunoréactivité de la bêta-amyloïde, restauration partielle de la protéine MAP2 et amélioration des fonctions cognitives. Le candidat-médicament a démontré des effets thérapeutiques dépendants de la dose sur la neuroinflammation et a montré un potentiel pour restaurer les réponses comportementales et sensorielles à des niveaux normaux.
Les données seront présentées sous forme d'un poster scientifique intitulé « Potentiel thérapeutique d'INM-901 pour atténuer la pathologie de la maladie d'Alzheimer : enseignements d'une étude à long terme sur un modèle murin 5xFAD » lors de l'AAIC 2025, prévue du 27 au 31 juillet.
InMed Pharmaceuticals (NASDAQ: INM) kündigte die Präsentation neuer präklinischer Daten für seinen Wirkstoffkandidaten INM-901 auf der bevorstehenden Internationalen Konferenz der Alzheimer-Gesellschaft (AAIC) 2025 in Toronto an. Die Studie bewertete die Langzeitbehandlungseffekte von INM-901 in einem 5xFAD-Mausmodell der fortgeschrittenen Alzheimer-Krankheit.
Die Forschung zeigte, dass INM-901 mehrere positive Effekte erzielte, darunter: Verringerung inflammatorischer Biomarker, Abnahme der Amyloid-Beta-Immunreaktivität, teilweise Wiederherstellung des MAP2-Proteins und Verbesserungen der kognitiven Funktion. Der Wirkstoffkandidat zeigte dosisabhängige therapeutische Effekte bei Neuroinflammation und zeigte vielversprechende Ansätze zur Wiederherstellung von Verhaltens- und sensorischen Reaktionen auf normale Werte.
Die Daten werden in einem wissenschaftlichen Poster mit dem Titel „Therapeutisches Potenzial von INM-901 zur Abschwächung der Alzheimer-Pathologie: Erkenntnisse aus einer Langzeitstudie mit dem 5xFAD-Mausmodell“ auf der AAIC 2025 präsentiert, die vom 27. bis 31. Juli stattfindet.
- INM-901 demonstrated significant reduction in multiple inflammatory biomarkers
- Drug showed dose-dependent improvements in cognitive function and behavior
- Treatment resulted in decreased amyloid-beta levels and partial restoration of MAP2 protein
- Multiple mechanisms of action targeting key pathological features of Alzheimer's disease
- None.
Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease ("AD") and dementia research.
Data will be presented in a scientific poster entitled, "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study". The Alzheimer's disease preclinical study measured hippocampal RNA expression, inflammatory markers, immunohistochemistry and behavioral differences following long-term treatment with INM-901 and as compared to healthy and to untreated diseased subjects in a well-established model.
This latest study evaluates INM-901 in the well-established 5xFAD AD mouse model, using a longer treatment duration and subjects with more advanced disease to validate and expand upon previous findings, which have demonstrated improvements in cognitive function, anxiety-related behavior, and sensory responsiveness.
Summary of INM-901 Long-term 5xFAD study:
Hippocampal RNA Expression - Several genes associated with inflammation, the endocannabinoid system, synaptic dysfunction and oxidative stress and apoptosis (cell death) were evaluated following treatment. In some cases, INM-901 demonstrated a dose-dependent trend towards a return to non-diseased baseline following treatment.
Inflammation - Treatment with INM-901 resulted in a significant reduction in the inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 and NfL, suggesting a dose-dependent therapeutic effect in neuroinflammation.
Immunohistochemistry - Amyloid-beta (Aβ) immunoreactivity is reduced following INM-901 treatment in a dose-dependent manner. MAP2, the microtubule-associated protein 2 is a protein found in the neurons, especially in the dendrites and is involved in neurite outgrowth and signal transduction of the neurons, is partially restored with INM-901 treatment.
Behavioral - Cognitive function, anxiety-related behavior, and sensory responsiveness were restored or approaching normal following INM-901 treatment.
Conference Details
Conference: Alzheimer's Association International Conference (AAIC)
Dates: July 27-31, 2025
Location: Toronto, Canada
Website: https://aaic.alz.org/
Presentation poster will be available on InMed's website following the conference.
Dr. Eric Hsu, SVP, Preclinical Research & Development at InMed, commented, "The latest data continues to build on mounting preclinical evidence of the potential of INM-901 as a multi-targeted treatment candidate for Alzheimer's disease. INM-901 demonstrates a differentiated therapeutic approach in mitigating Alzheimer's pathology and we are excited to share the results from this study with the Alzheimer's disease community at the AAIC."
INM-901: Targeting multiple biological pathways in Alzheimer's disease
INM-901 is a proprietary small molecule drug candidate under development for the treatment of AD, with multiple mechanisms of action targeting key pathological features of the disease. Key attributes include:
Behavioral Improvements: INM-901 demonstrates positive trends in cognitive function, anxiety-related behavior, and sensory responsiveness.
Anti-Inflammatory Action: INM-901 demonstrates strong neuroinflammatory modulation in AD pathology.
Neuroprotection: INM-901 significantly reduces amyloid-beta-induced cell death.
Neuronal Regeneration: INM-901 promotes neurite outgrowth, indicating its ability to enhance neuronal connectivity and function.
Molecular Validation: mRNA data aligns with behavioral findings, supporting observed improvements in cognition, memory and neurogenesis.
About AAIC
The Alzheimer's Association International Conference ('AAIC') is a premier global event dedicated to advancing research and innovation in the fields of dementia and cognitive health. This annual gathering unites scientists, medical professionals, and thought leaders from across the globe to share the most recent discoveries, developments, and best practices in the field. Topics range from groundbreaking research to new care techniques, all focused on improving early diagnosis, managing risks, and enhancing approaches to Alzheimer's and related diseases.
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-Q, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260250
FAQ
What are the key findings of InMed's INM-901 preclinical study for Alzheimer's disease?
When and where will InMed (NASDAQ: INM) present its INM-901 Alzheimer's data?
What are the main mechanisms of action of INM-901 for Alzheimer's treatment?
How does INM-901 affect behavioral symptoms in Alzheimer's disease models?
What inflammatory markers were reduced by INM-901 in the Alzheimer's study?
